Availability of soluble PD-L1 as a biomaker that predicts the response of therapy with anti-PD-1 antibody for the patients with malignant melanoma

Availability of soluble PD-L1 as a biomaker that predicts the response of therapy with anti-PD-1 antibody for the patients with malignant melanoma - Investigation of biomakers that predicts the response of therapy with anti-PD-1 antibody for the patients with malignant melanoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018264

Enrollment

Registered

2015-10-01

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant melanoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients who were diagnosed as malignant melanoma and unable to remove tumors surgically. 2) patients whose age are more than 20y 3) patients who agree to register this study after an informed concent

Exclusion criteria

Exclusion criteria: 1) patients who offer withdrawal from the entry of this study 2) patients whose age are under 20y 3) patients with multiple cancers 4) patients who have allergy to anti-PD-1 antibody 5) patients who received other immune therapy than anti-PD-1 antibody

Design outcomes

Primary

Measure	Time frame
tumor size, sites, sum of the tumor size (representative of five), serum concentration of soluble PD-L1	—

Secondary

Measure	Time frame
patients' background serum concentration of LDH and 5-SCD	—

Countries

Japan

Contacts

Public ContactShimpei Kasagi

Kobe university hospital Department of laboratory medicine

kobe470@med.kobe-u.ac.jp081-78-382-6312

Outcome results